Spontaneous autoimmunity sufficiently potent to induce diabetes mellitus is insufficient to protect against insulinoma

Journal of Immunology

Volumn 183, Issue 3, 2009, Pages 1705-1714

  Zwicker, Kelley ^a   Chatten, Christa ^a   Gratton, Kathy ^a   Demetrick, Doug ^a   Serra, Pau ^b   Shameli, Afshin ^b   Santamaria, Pere ^b   Bathe, Oliver F ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD8 ANTIGEN; GLUCOSE 6 PHOSPHATASE; INSULIN; ISLET SPECIFIC GLUCOSE 6 PHOSPHATASE CATALYTIC SUBUNIT RELATED PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; DOWN REGULATION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INSULINOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; TRANSGENE; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS; IMMUNE TOLERANCE; INSULINOMA; MICE; MICE, TRANSGENIC; NEOPLASMS;

EID: 68149166496     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0800902     Document Type: Article

References (35)

1. Bathe, O. F., N. Dalyot-Herman, and T. R. Malek. 2003. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment. BMC Cancer 3: 21.
2. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66: 470-476.
3. Seliger, B., A. Hohne, D. Jung, M. Kallfelz, A. Knuth, E. Jaeger, H. Bernhard, F. Momburg, R. Tampe, and C. Huber. 1997. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp. Hematol. 25: 608-614. (Pubitemid 27298341)
4. Zwicker, K. A., and O. F. Bathe. 2004. Exploring the relationship between tumor immunity and autoimmunity. In Recent Research Developments in Cancer. S. G. Pandalai, ed. Transworld Research Network, Kerala, India, p. 343-378.
5. Smith, M. E., S. G. Marsh, J. G. Bodmer, K. Gelsthorpe, and W. F. Bodmer. 1989. Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc. Natl. Acad. Sci. USA 86: 5557-5561.
6. Zucchelli, S., P. Holler, T. Yamagata, M. Roy, C. Benoist, and D. Mathis. 2005. Defective central tolerance induction in NOD mice: genomics and genetics. Immunity 22: 385-396.
7. Folkman, J., K. Watson, D. Ingber, and D. Hanahan. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
8. Grant, S. G., I. Seidman, D. Hanahan, and V. L. Bautch. 1991. Early invasiveness characterizes metastatic carcinoid tumors in transgenic mice. Cancer Res. 51: 4917-4923.
9. Hanahan, D., G. Christofori, P. Naik, and J. Arbeit. 1996. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur. J. Cancer 32A: 2386-2393.
10. Naik, P., J. Karrim, and D. Hanahan. 1996. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev. 10: 2105-2116. (Pubitemid 26303867)
11. + T cells expressing identical endogenous TCR-α chains. J. Immunol. 157: 4726-4735.
12. Verdaguer, J., D. Schmidt, A. Amrani, B. Anderson, N. Averill, and P. Santamaria. 1997. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J. Exp. Med. 186: 1663-1676.
13. Tough, D. F., and J. Sprent. 1994. Turnover of naive- and memory-phenotype T cells. J. Exp. Med. 179: 1127-1135.
14. Martin, C. C., L. J. Bischof, B. Bergman, L. A. Hornbuckle, C. Hilliker, C. Frigeri, D. Wahl, C. A. Svitek, R. Wong, J. K. Goldman, et al. 2001. Cloning and characterization of the human and rat islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) genes. J. Biol. Chem. 276: 25197-25207.
15. Sotomayor, E. M., I. Borrello, E. Tubb, J. P. Allison, and H. I. Levitsky. 1999. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc. Natl. Acad. Sci. USA 96: 11476-11481.
16. Sotomayor, E. M., I. Borrello, F. M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98: 1070-1077.
17. + T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol. 163: 102-110.
18. + T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194: 707-717.
19. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
20. + T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J. Immunol. 165: 6731-6737.
21. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y. X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17: 737-747.
22. Wilcox, R. A., D. B. Flies, G. Zhu, A. J. Johnson, K. Tamada, A. I. Chapoval, S. E. Strome, L. R. Pease, and L. Chen. 2002. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109: 651-659.
23. Bai, X. F., J. Liu, O. Li, P. Zheng, and Y. Liu. 2003. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J. Clin. Invest. 111: 1487-1496.
24. Garcia-Lora, A., M. Martinez, I. Algarra, J. J. Gaforio, and F. Garrido. 2003. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int. J. Cancer 106: 521-527.
25. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25: 677-686.
26. Gabrilovich, D. I., V. Bronte, S. H. Chen, M. P. Colombo, A. Ochoa, S. Ostrand-Rosenberg, and H. Schreiber. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67: 425.
27. + myeloid cells. J. Immunol. 166: 5398-5406.
28. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.
29. Tien, A. H., L. Xu, and C. D. Helgason. 2005. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res. 65: 2947-2955.
30. + T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol. 167: 5583-5593.
31. + T cells. J. Clin. Invest. 116: 2777-2790.
32. Yoon, J. W., H. S. Jun, and P. Santamaria. 1998. Cellular and molecular mechanisms for the initiation and progression of β cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 27: 109-122.
33. Direkze, N. C., K. Hodivala-Dilke, R. Jeffery, T. Hunt, R. Poulsom, D. Oukrif, M. R. Alison, and N. A. Wright. 2004. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64: 8492-8495.
34. Silzle, T., G. J. Randolph, M. Kreutz, and L. A. Kunz-Schughart. 2004. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int. J. Cancer 108: 173-180.
35. Lieubeau, B., M. F. Heymann, F. Henry, I. Barbieux, K. Meflah, and M. Gregoire. 1999. Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development. Int. J. Cancer 81: 629-636.